Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseGlobeNewsWire • 10/04/23
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023GlobeNewsWire • 09/25/23
Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets ConferenceGlobeNewsWire • 09/20/23
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in AustraliaGlobeNewsWire • 09/12/23
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease ModelGlobeNewsWire • 08/28/23
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/23
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 08/10/23
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson's Disease and Movement Disorders®GlobeNewsWire • 08/07/23
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology ConferenceGlobeNewsWire • 07/31/23
Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's AssetSeeking Alpha • 05/31/23
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/12/23
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 05/12/23
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/08/23
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's DiseaseGlobeNewsWire • 05/03/23
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 MeetingGlobeNewsWire • 03/29/23
Gain Therapeutics Reports Full Year 2022 Financial Results and Business UpdateGlobeNewsWire • 03/23/23
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion LeadersGlobeNewsWire • 03/22/23
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research ProgramGlobeNewsWire • 03/21/23
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/09/23
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposiumGlobeNewsWire • 02/27/23
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/22
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 11/10/22